Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Mongodb Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Mongodb Inc trades at $350 (market cap $30.05B). The key difference: Mongodb Inc is far larger — about 3.4× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Mongodb Inc for 46 Days on average.
| KYMR | MDB | |
|---|---|---|
Market Cap | $8.87B | $30.05B |
Volume | 779,107 | 3,027,814 |
Sector | Health | Technology |
52-Week High | $127.31 | $472.29 |
52-Week Low | $55.80 | $225.95 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $8.26B | $27.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MDB trades at $356.29, down 6.56% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q3 2026 results pending. Revenue has grown from $874 million in 2022 to $2.01 billion in 2025, though net losses persist, narrowing to -$129 million in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
The outlook is cautiously optimistic, with a consensus price target of $456.76 implying 28% upside. Key opportunities include raised long-term revenue targets exceeding 20% growth and AI-driven product expansion. Risks involve continued net losses, high valuation multiples, and execution challenges amid leadership changes. Analyst consensus is strongly bullish with 80% buy ratings, but stock volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
